DigiPall; a Trial of Digital Patient Reported Outcome and Biomarker Monitoring in Palliative Care
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDavid Blum
About this trial
The aim of this study is to test if a system consisting of a wearable device measuring heartbeats and steps, together with daily communication with a chatbot on the smartphone asking the patients about their symptoms and giving tips, can reduce unplanned hospital readmissions and improve well-being in advanced cancer and severely ill patients.
Eligibility criteria
Qualifiers
Patients with established diagnosis of a metastatic cancer/severe illness with limited life expectancy receiving palliative care services
Estimated life expectancy <24 months (physician's guess)/ >3 months
Karnofsky Index ≥ 50% / ECOG≤ 2
Aged >18 years
Disqualifiers
Patients under curative treatment
Relevant cognitive impairment
Trial design
Treatments tested in this trial
- DigiPall
Treatment groups
382 Participants
are divided into 2 treatment groupsSponsors and collaborators
David Blum
Lead sponsor
University of Zurich
Sponsor institution
Zurich University of Applied Sciences
Collaborator
Source ClinicalTrials.gov